Thus, when drugs are ultimately approved based on the use of biomarkers, the description of the medication’s approved uses, which is printed on the label, might be more restrictive – that is, it might reduce the size of the patient population for which the drug is intended. For example, a drug broadly approved for “arthritis” – inflammation of joints that may be due to dozens of different disease processes – can be more widely marketed than one approved to treat only the arthritis that accompanies psoriasis or gout.
于是，当药物最终在使用生物指标的基础上获得批准时，对该药物的批准用途的描述——将写在标签上——将更加严格，也就是说，将缩小该药物适用病患的数量规模。比如，被宽泛地批准用于“关节炎”——多种疾病都可能引起的关节炎症——的药物可以被更广泛推广，而只准用于伴随着牛皮癣和痛风的关节炎的药物则否。